Although the development of therapies and tools for the improved management of heart
failure (HF) continues apace, day‐to‐day management in clinical practice is often far from …

Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range
ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of …

Background: Little is known regarding the impact of socioeconomic factors on the use of
evidence-based therapies and outcomes in patients with heart failure with reduced ejection …

Background: Outcomes in heart failure with reduced ejection fraction (HFrEF) are influenced
by access and adherence to guideline-directed medical therapy. Our objective was to study …

Background: Slow uptake of sacubitril/valsartan in patients with heart failure with reduced
ejection fraction has been reported, which may negatively impact clinical outcomes. We …

Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart
failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We …

Abstract Purpose In PARADIGM-HF, sacubitril/valsartan showed a significant reduction in
mortality and hospitalization for patients with heart failure with reduced ejection fraction …

Importance Low-density lipoprotein cholesterol (LDL-C)–lowering therapies are a
cornerstone of prevention in atherosclerotic cardiovascular disease. With the introduction of …

BACKGROUND: Despite growing interest in value-based models, utilization patterns and
costs for heart failure (HF) admissions are not well understood. We sought to characterize …

Background Better understanding of recent sacubitril/valsartan prescription patterns may
help identify factors that influence its use. The aim of the study was to characterize …